We describe for the first time, to our knowledge, that FoxO1 acts as a direct transcriptional activator of Rictor during BTK inhibitor therapy, leading to mTORC2-mediated phosphorylation of Akt (S473) and thus contributing to the survival of CLL cells. Here, FOXO1 is linked to B-cell chronic lymphocytic leukemia.